Skip to navigation menu Skip to content
Informational Alert

Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

High Priority Alert

Masking and Visitation Changes: Due to high rates of respiratory illnesses in our community, we’ve made changes to our masking and visitation guidelines .

Illustration of a calendarIllustration of a document pageIllustration of a heart over a handIllustration of an envelopeIllustration of the letter i inside a circleIllustration of a map markerIllustration of a caduceusIllustration of a user with a plus signIllustration of a telephoneIllustration of a question mark inside a circleIllustration of a video cameraDocument with a PDF label
Current Research Studies

REVERSING AUTOIMMUNITY THROUGH CELL THERAPY

REACT-01

What is the goal of the study?

This phase 1, open-label, non-randomized study will enroll pediatric and young adult research participants with treatment-refractory Systemic Lupus Erythematosus (SLE), to examine the safety, feasibility, and efficacy of administering T cell products derived from peripheral blood mononuclear cells (PBMC) that have been genetically modified using self-inactivating (SIN) lentiviral vector to express CD19 -specific chimeric antigen receptor (CAR) with the selection suicide marker EGFRt. The primary objectives of the study will be to determine the feasibility of manufacturing the cell product, the safety of the T cell product infusion, and to describe the full toxicity profile of anti-CD19 CAR T cells in SLE.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: